Deutsches Herzzentrum Muenchen
Munich, 80636, Germany
NCT Number: NCT00140465
The purpose of the study is to test whether an increase of the maintenance dose of clopidogrel from 75 to 150 mg per day results in an additional suppression of ADP-induced platelet aggregation
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 4
Munich, 80636, Germany
In patients treated with coronary stents clopidogrel therapy is usually initiated with a 300 to 600 mg loading dose. In the CREDO trial it was shown that a 300 mg loading dose results in a reduction of ischemic events after percutaneous coronary intervention (PCI) if given 6 hours prior to the procedure. An antiplatelet effect similar to that achieved by chronic therapy with 75 mg/day is reached within 2 hours when the high 600 mg loading is administered. The 600 mg loading dose has been shown to be safe and effective in preventing thrombotic events following coronary stent implantation. Recently, it was shown that in patients with stable angina and administration of the 600 mg loading dose at least two hours prior to PCI concomitant therapy with a GP IIb/IIIa antagonist does not result in a further reduction of the incidence of thrombotic events. In contrast to a number of investigations with different loading doses, no trials have been performed comparing different clopidogrel maintenance doses. Recently, it was shown that administration of a 600 mg loading dose in patients already on chronic clopidogrel therapy (75 mg/day) results in an additional significant increase in inhibition of adenosine diphosphate (ADP-) induced platelet aggregation. Therefore, it is possible that an increase of the clopidogrel maintenance dose in patients with chronic clopidogrel therapy also results in a more pronounced inhibition of platelet aggregation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
after PCI
Other names: Iscover, Plavix
Time frame: 30 days after the intervention
Time frame: 30 days after the intervention
Time frame: P2Y12 inhibition measured by point-of-care test
Deutsches Herzzentrum Muenchen
Other
A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02579655
Brain Diseases, Cardiovascular Diseases
Calgary, Alberta, Canada
View Trial DetailsNCT04580017
Angina Pectoris, Angina, Unstable
Hammam Sousse, Sousse Governorate, Tunisia
View Trial DetailsNCT00248352
Arterial Occlusive Diseases, Arteriosclerosis
Ottawa, Ontario, Canada
View Trial DetailsNCT00241735
Cardiovascular Diseases, Coronary Disease
View Trial Details